A Network Meta‐Analysis of Non‐Melanoma Skin Cancer (NMSC) Treatments: Efficacy and Safety Assessment
Authors:
- 20 June 2017
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 118 (11) , 3686-3695
Abstract
The mainstream treatments for non‐melanoma skin cancer (NMSC) include photodynamic therapy (PDT), surgery excision (SE), cryotherapy (CT), imiquimod (IM), radiotherapy (RT), 5‐fluorouracil (FU), and vehicle (VE). Our network meta‐analysis (NMA) was aimed at evaluating the efficacy and safety of these seven treatments and providing superior ones. After searching the trials from Embase and PubMed and screening with our criteria, we conducted the NMA with software R 3.2.3 and STATA 13.0. Complete lesion response (CLR), complete lesion clearance (CLC), cumulative recurrence probabilities (CRP), and adverse effects (AEs) were considered as outcomes and displayed as odds ratios (ORs) and 95% credible intervals (CrI). The surface under the cumulative ranking curve (SUCRA) was calculated to rank each treatment on each index. The consistency of direct and indirect evidence was also assessed by node‐splitting and heat plot methods. Data from 18 trials with 3706 patients were included. Both IM and SE were demonstrated significantly higher CLR rate than VE (OR = 9.12, 95% CrI = 1.92–47.5; OR = 26.1, 95% CrI = 1.92‐347; respectively), while only IM was proved to be statistically better than VE in CLC rate (OR = 7.03, 95% CrI = 1.51–32.8). No significant difference was observed concerning CRP, and IM was more likely to induce AEs than VE (OR = 4.44, 95% CrI = 1.58–13.9). The SUCRA results indicated that SE was the treatment with best ranking in the entire three efficacy indexes and a relatively high safety. Taking efficacy and safety into account, our study recommended SE as the optimal regimen for NMSC with high efficacy considering CLR, CLC, and CRP and moderate AEs when compared with other interventions. J. Cell. Biochem. 118: 3686–3695, 2017.Keywords
This publication has 37 references indexed in Scilit:
- Evidence Synthesis for Decision Making 4Medical Decision Making, 2013
- Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trialThe Lancet Oncology, 2013
- Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trialsBritish Journal of Dermatology, 2012
- Trends in the incidence of nonmelanoma skin cancer in Denmark 1978–2007: Rapid incidence increase among young Danish womenInternational Journal of Cancer, 2010
- A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8–20 mm), with a 12‐month follow‐up.Journal of the European Academy of Dermatology and Venereology, 2008
- Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database studyInternational Journal of Cancer, 2007
- Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studiesJournal of the American Academy of Dermatology, 2004
- Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% creamJournal of the American Academy of Dermatology, 1999
- Guidelines for the management of basal cell carcinomaBritish Journal of Dermatology, 1999
- Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's diseaseBritish Journal of Dermatology, 1996